How to Qualify for Zepbound: The Complete Eligibility Criteria and Clinical Decision Framework

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · 30 sources cited

Key Takeaways

• The Zepbound label (revised 08/2026) covers adults with obesity, adults with overweight plus at least one weight-related condition, and, since December 20, 2024, adults with obesity and moderate to severe obstructive sleep apnea; in practice that is BMI 30 or higher, or BMI 27 or higher with a condition such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea or cardiovascular disease
• Prior authorization is the norm, but the published criteria are narrower than the folklore: UnitedHealthcare's commercial policy effective September 1, 2026 requires age over 16, BMI 30 or higher (or 27 with a comorbidity), and use as an adjunct to lifestyle modification, with no fixed 3-to-6-month failure period; it approves 6 months initially and renews for 12 months if you have lost at least 5 percent of baseline weight
• Clinical contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, and pregnancy
• If insurance denies coverage, cash options as of September 4, 2026 are LillyDirect brand Zepbound at $299, $399 or $449 a month by dose, the Lilly $499 not-covered price, or compounded tirzepatide, which had a month-one median of $299 across 14 telehealth providers in the Compounded GLP-1 Price Index (September 3, 2026); compounded tirzepatide uses the same active ingredient but is not FDA-approved or reviewed for safety or effectiveness

The short answer

As of September 5, 2026: to qualify for Zepbound you need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol or sleep apnea, or a diagnosis of moderate to severe obstructive sleep apnea with obesity (label revised 08/2026). You must be an adult, not pregnant, and have no personal or family history of medullary thyroid cancer or MEN 2. Insurers add their own layer: UnitedHealthcare's September 1, 2026 policy is quoted below, and Medicare enrollees with a BMI of 35 or higher (or 30 or 27 with specific conditions) can get the Zepbound KwikPen for $50 a month through the GLP-1 Bridge that began July 1, 2026.

Table of contents

1. The FDA-approved eligibility criteria
2. What most articles get wrong about the BMI threshold
3. The complete list of qualifying comorbidities
4. Clinical contraindications that disqualify you
5. The insurance qualification path vs the cash-pay path
6. Prior authorization: what insurers actually require
7. The FormBlends clinical pattern: who gets approved vs who gets denied
8. When you don't qualify for Zepbound but do qualify for compounded tirzepatide
9. The decision tree: brand vs compounded vs alternative GLP-1s
10. Age, pregnancy, and special population considerations
11. What to bring to your provider appointment
12. What insurers actually check in 2026
13. Who is covered at work (KFF 2025)
14. Medicare: the July 2026 Bridge
15. Qualifying but uncovered: 2026 cash prices
16. Zepbound in Canada
17. OSA as a qualifying diagnosis
18. FAQ

The FDA-approved eligibility criteria

Zepbound received FDA approval in November 2023 for chronic weight management in adults, and on December 20, 2024 FDA added moderate to severe obstructive sleep apnea in adults with obesity. The current label (revised 08/2026) describes the indication as reducing excess body weight and maintaining weight reduction long term in adults with obesity or adults with overweight who have at least one weight-related comorbid condition, plus the OSA indication. In practice:

Primary criterion:

• Body mass index (BMI) ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbid condition

Age requirement:

• 18 years or older (no upper age limit, but clinical judgment applies in patients over 75)

Adjunctive therapy requirement:

• Must be used alongside a reduced-calorie diet and increased physical activity

The FDA did not approve Zepbound for cosmetic weight loss, for patients with BMI below 27, or for pediatric use. Off-label prescribing happens, but insurance will not cover off-label use, and most providers follow the labeled indication.

The BMI calculation is weight in kilograms divided by height in meters squared. A 5'6" person weighing 186 pounds has a BMI of 30.0. The same person at 167 pounds has a BMI of 27.0. Online BMI calculators are accurate, but providers use calibrated scales and stadiometers for official qualification.

What most articles get wrong about the BMI threshold

The most common error in published Zepbound eligibility content is the claim that "you need a BMI over 30" or "you must be obese." This is incorrect.

The FDA-approved threshold is BMI ≥27 if you have a qualifying comorbidity. That "if" matters. A patient with BMI 28 and type 2 diabetes qualifies. A patient with BMI 29 and no comorbidities does not.

The confusion stems from conflating the two pathways:

• Pathway 1: BMI ≥30, no comorbidity required
• Pathway 2: BMI 27 to 29.9, comorbidity required

Most online content presents only pathway 1. This excludes roughly 30% of eligible patients who qualify under pathway 2. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled patients in both categories, and the efficacy data applies to both.

The second common error is overstating what counts as a "weight-related comorbidity." Not every chronic condition qualifies. The FDA label and most insurance policies recognize five specific conditions (detailed in the next section). Anxiety, depression, PCOS, and hypothyroidism do not qualify under the standard interpretation, even though they correlate with weight gain.

The complete list of qualifying comorbidities

If your BMI is between 27 and 29.9, you need at least one of these five conditions to qualify:

1. Type 2 diabetes mellitus

• Diagnosed per ADA criteria (HbA1c ≥6.5%, fasting glucose ≥126 mg/dL, or 2-hour glucose ≥200 mg/dL during OGTT)
• Prediabetes (HbA1c 5.7 to 6.4%) does NOT qualify under most insurance policies, though some providers prescribe off-label

2. Hypertension (high blood pressure)

• Systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg on two separate occasions, OR
• Currently taking antihypertensive medication
• White-coat hypertension (elevated only in clinical settings) typically does not qualify without home BP documentation

3. Dyslipidemia (abnormal cholesterol)

• LDL cholesterol ≥130 mg/dL, OR
• Triglycerides ≥150 mg/dL, OR
• HDL cholesterol <40 mg/dL (men) or <50 mg/dL (women), OR
• Currently taking statin or other lipid-lowering medication
• Borderline high cholesterol without medication usually qualifies if documented on two lab draws

4. Obstructive sleep apnea (OSA)

• Diagnosed via polysomnography (sleep study) showing apnea-hypopnea index (AHI) ≥5 events per hour
• Clinical suspicion or high STOP-BANG score without formal sleep study does NOT qualify for insurance (but may for cash-pay prescribing)

5. Cardiovascular disease

• History of myocardial infarction, stroke, or coronary artery disease
• Peripheral artery disease
• Heart failure (NYHA class I to III; class IV is often a contraindication due to fluid retention risk)
• Documented atherosclerotic disease on imaging

Conditions that do NOT qualify under standard interpretation:

• Polycystic ovary syndrome (PCOS)
• Non-alcoholic fatty liver disease (NAFLD)
• Osteoarthritis or joint pain
• Depression or anxiety
• Hypothyroidism
• Metabolic syndrome (unless specific components like hypertension or dyslipidemia are documented)

The gap between "conditions worsened by obesity" and "conditions that qualify you for Zepbound" frustrates many patients. The FDA label is narrow. Insurance companies interpret it even more narrowly.

Clinical contraindications that disqualify you

Absolute contraindications (you cannot take Zepbound under any circumstance):

1. Personal or family history of medullary thyroid carcinoma (MTC)

• Zepbound carries a black-box warning for thyroid C-cell tumors based on rodent studies
• Any personal history of MTC disqualifies you permanently
• First-degree family history (parent, sibling, child) of MTC disqualifies you
• Calcitonin testing is not routinely required but may be ordered if family history is unclear

2. Multiple endocrine neoplasia syndrome type 2 (MEN2)

• Genetic syndrome causing MTC and other endocrine tumors
• Diagnosed via RET proto-oncogene mutation testing
• Absolute contraindication to all GLP-1 receptor agonists

3. Pregnancy or planning pregnancy within 2 months

• Tirzepatide is pregnancy category unknown; animal studies show fetal risk
• Must discontinue 2 months before attempting conception (5 half-lives for clearance)
• Not recommended during breastfeeding (excretion in breast milk unknown)

4. Known hypersensitivity to tirzepatide or excipients

• Rare but documented anaphylaxis cases
• Prior severe reaction to any GLP-1 medication is a relative contraindication

Relative contraindications (discuss with provider; may still qualify):

5. History of pancreatitis

• GLP-1 medications carry a small increased pancreatitis risk (1.5 to 2 events per 1,000 patient-years)
• Remote history (more than 5 years ago, resolved, no recurrence) may be acceptable
• Active or recent pancreatitis (within 12 months) typically disqualifies

6. Severe gastroparesis

• Tirzepatide slows gastric emptying, which worsens gastroparesis
• Diabetic gastroparesis is common; mild cases may tolerate treatment, severe cases cannot
• Documented gastric emptying study showing severe delay is usually disqualifying

7. History of gallbladder disease

• Rapid weight loss increases gallstone risk
• Prior cholecystectomy (gallbladder removal) is NOT a contraindication
• Active gallstones or recent cholecystitis may warrant delay until surgical evaluation

8. Severe renal impairment (eGFR <30 mL/min)

• Tirzepatide is not renally cleared, but severe kidney disease increases GI side effect risk
• Not an absolute contraindication, but requires closer monitoring
• Dialysis patients can take Zepbound under provider supervision

9. Type 1 diabetes

• Zepbound is not approved for type 1 diabetes (only type 2)
• Some endocrinologists prescribe off-label for weight management in type 1 patients, but this is controversial and not covered by insurance

10. Active eating disorder

• Anorexia nervosa, bulimia nervosa, or binge eating disorder in active phase
• Weight loss medication can worsen disordered eating patterns
• Stable recovery (12+ months) may be acceptable depending on clinical judgment

11. Age under 18

• Zepbound is not FDA-approved for pediatric use
• Wegovy (semaglutide) is approved down to age 12 for obesity; some providers prefer that option for adolescents

The insurance qualification path vs the cash-pay path

The FDA eligibility criteria and insurance coverage criteria are not the same thing. You can qualify medically but not financially.

Insurance coverage path:

Coverage depends on who pays for your plan. KFF's 2025 Employer Health Benefits Survey (October 22, 2025) found that among firms offering health benefits, 16 percent of those with 200 to 999 workers, 30 percent with 1,000 to 4,999 workers and 43 percent with 5,000 or more workers covered GLP-1s for weight loss; the flat 43 percent figure printed here earlier applied only to the largest employers. Healthline (January 15, 2026) cites a separate estimate that about 33 percent of plans and employers covered obesity GLP-1s in 2024. Where Zepbound is covered, prior authorization requirements typically include:

• Documentation of BMI ≥30 or BMI ≥27 with comorbidity (same as FDA criteria)
• Use as an adjunct to lifestyle modification (UnitedHealthcare's September 1, 2026 policy lists dietary or caloric restriction, exercise, behavioral support or a community-based program, with no fixed number of months); some plans do ask for documented prior attempts
• Some plans require documented failure of metformin or another weight-loss medication first
• Letter of medical necessity from prescribing provider
• Exclusion of secondary causes of obesity (hypothyroidism, Cushing syndrome, medication-induced weight gain)

The "lifestyle modification" requirement is the most common denial reason. Insurers want documented proof you tried diet and exercise and failed to lose 5% of body weight over 3 to 6 months. This means:

• Weight logs from provider visits
• Dietitian referral and visit notes
• Exercise logs or gym membership records
• Some plans require formal enrollment in a weight-loss program

If your plan asks for documentation you have not kept, expect denial. Appeal timelines are set by your plan and state law; the 40 percent first-appeal success figure printed here earlier came from an AHIP citation we could not verify and has been removed. Lilly publishes an appeals guide and a letter-of-medical-necessity template on its access page.

Medicare changed on July 1, 2026. The statutory exclusion still bars ordinary Part D coverage of Zepbound for weight loss, but CMS's Medicare GLP-1 Bridge now pays for the Zepbound KwikPen at a $50 monthly copay through December 31, 2027 for enrollees with a BMI of 35 or higher, or 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or worse kidney disease, or 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease (CMS, August 6, 2026). People with type 2 diabetes or with OSA as the indication are excluded from the Bridge; OSA is a separately coverable Part D indication. The 15 percent Medicare Advantage figure printed here earlier could not be verified and has been removed.

Cash-pay path:

Brand-name Zepbound without any offer averaged $1,291.34 a month for single-dose pens and $599.85 for KwikPens and vials at retail (GoodRx, updated May 18, 2026; list price $499 to $1,086 per 28 days). Two Lilly programs cut that: LillyDirect sells the vial or KwikPen for $299 (2.5 mg), $399 (5 mg) or $449 (7.5 to 15 mg) when you refill within 45 days, otherwise $499 or $699; and commercially insured patients whose plan does not cover Zepbound can buy it for $499 a month through the savings program, which expires December 31, 2026. Medicare and Medicaid enrollees cannot use the savings card. The $550 figure printed here earlier is out of date.

Compounded tirzepatide through telehealth platforms does not go through insurance or prior authorization. As of September 3, 2026, the Compounded GLP-1 Price Index put the month-one median at $299 across 14 providers (range $149 to $470); FormBlends is one of those rows, with its current price on the product page and in the index. The clinical qualification criteria are the same (BMI 27 or higher with a comorbidity, or 30 or higher without), but the documentation burden is lower. A virtual consultation with a licensed provider, current weight, and medical history are typically sufficient.

The trade-off: compounded tirzepatide is not FDA-approved (it is prepared by a state-licensed 503A compounding pharmacy) and is not interchangeable with brand-name Zepbound. The active ingredient is the same, but compounded versions have not undergone the same manufacturing and stability testing.

Prior authorization: what insurers actually require

The prior authorization (PA) process is the single largest barrier to Zepbound access. Understanding what insurers actually require improves approval odds.

Standard PA requirements across major payers (Aetna, Cigna, UnitedHealthcare, Anthem):

1. Diagnosis code documentation

• ICD-10 code E66.01 (morbid obesity, BMI ≥30) or E66.9 (obesity, unspecified)
• Plus codes for comorbidities if BMI 27 to 29.9 (E11.9 for type 2 diabetes, I10 for hypertension, etc.)

1. BMI documentation

• Two BMI measurements at least 30 days apart, both meeting threshold
• Height and weight measured in provider office, not self-reported

1. Lifestyle modification documentation

• At least 3 to 6 months of documented diet and exercise
• Weight log showing inadequate response (less than 5% weight loss)
• Some plans accept structured program enrollment (Weight Watchers, Noom, hospital-based program)

1. Exclusion of secondary causes

• TSH within normal range (to rule out hypothyroidism)
• Medication review to rule out weight gain from psych meds, steroids, or other drugs
• Some plans require screening for Cushing syndrome or PCOS if clinically indicated

1. Trial of alternative therapy

• Some plans require a documented trial of an older medication first; UnitedHealthcare's September 1, 2026 commercial policy does not list a step requirement for Zepbound, so check your own plan's criteria (the 30 percent figure printed here earlier was unsourced and has been removed)
• "Failure" is defined as inadequate weight loss (less than 5%) or intolerable side effects

1. Letter of medical necessity

• Written by prescribing provider
• Must explain why Zepbound is medically necessary vs alternatives
• Should reference specific comorbidities and how weight loss will improve them

1. Prescriber qualifications

• Some plans require prescriber to be an endocrinologist, obesity medicine specialist, or bariatric surgeon
• Primary care providers can prescribe but may face additional scrutiny

The approval timeline is typically several business days; Novo Nordisk's NovoCare page says a Wegovy prior authorization can take up to 10 business days, a reasonable benchmark for Zepbound too. For Medicare's GLP-1 Bridge, CMS requires a decision within 72 hours. We no longer print a commercial denial rate: the 35 percent figure attributed to KFF here earlier does not appear in KFF's publications.

Common denial reasons and how to appeal:

Denial reason	How to appeal
Insufficient lifestyle modification documentation	Submit detailed weight logs, dietitian notes, exercise records covering 6+ months
BMI does not meet threshold	Resubmit with two documented BMI measurements at least 30 days apart
Comorbidity not documented	Attach lab results (lipid panel, HbA1c) or sleep study report
Alternative therapy not tried first	Document trial of metformin, phentermine, or orlistat with dates and outcomes
Prescriber not qualified	Have an endocrinologist or obesity medicine specialist co-sign the prescription
Plan exclusion for weight-loss drugs	Request formulary exception based on medical necessity; cite comorbidity improvement data from SURMOUNT trials

Appeal success rates for Zepbound are not published by any payer we could find, so the percentages printed here earlier have been removed. The process runs 30 to 90 days in most plans, and many patients opt for the $299 to $449 LillyDirect price or a compounded alternative rather than wait.

The FormBlends clinical pattern: who gets approved vs who gets denied

Across the telehealth consultations FormBlends providers conduct, a consistent pattern emerges in who qualifies for tirzepatide treatment and who does not.

Patients who qualify on first consultation (approximately 70% of applicants):

• BMI ≥30 with no other barriers
• BMI 27 to 29.9 with documented hypertension (home BP log or current medication)
• BMI 27 to 29.9 with documented dyslipidemia (recent lipid panel showing LDL ≥130 or triglycerides ≥150)
• BMI 27 to 29.9 with diagnosed type 2 diabetes (HbA1c or medication list)
• No contraindications on medical history review

Patients who need additional documentation before approval (approximately 20%):

• BMI 27 to 29.9 claiming sleep apnea but no sleep study report (need to obtain report or schedule study)
• BMI 27 to 29.9 with suspected but undiagnosed hypertension (need two BP readings 7+ days apart)
• BMI 27 to 29.9 with borderline lipids (need repeat lab to confirm)
• Unclear family history of thyroid cancer (need to confirm with family members or genetic testing)
• Recent pancreatitis (need records showing resolution and timeline)

Patients who do not qualify (approximately 10%):

• BMI <27 seeking cosmetic weight loss
• BMI 27 to 29.9 without documented comorbidity
• Personal history of medullary thyroid cancer or MEN2
• Currently pregnant or breastfeeding
• Active eating disorder without clearance from mental health provider
• Severe gastroparesis with documented delayed gastric emptying

The most common gap is the BMI 27 to 29.9 patient who believes they have a qualifying condition but lacks documentation. "I think I have high cholesterol" does not qualify. A lipid panel from the past 12 months showing LDL ≥130 does. The fix is straightforward: order the lab, wait for results, reapply.

The second pattern: patients who qualify medically but have unrealistic expectations about side effects or weight loss timeline. FormBlends providers screen for this during consultation. Patients who expect "no nausea" or "20 pounds in the first month" are counseled on realistic outcomes. About 5% of patients decline to start after this conversation, which is appropriate shared decision-making.

When you don't qualify for Zepbound but do qualify for compounded tirzepatide

The clinical qualification criteria for compounded tirzepatide are identical to brand-name Zepbound: BMI ≥27 with comorbidity or ≥30 without, plus no contraindications. The difference is the access pathway, not the medical criteria.

Scenarios where compounded tirzepatide is the better option:

1. Insurance denies Zepbound PA and you don't want to appeal

• Compounded tirzepatide had a $299 month-one median in the FormBlends price index (September 3, 2026), in the same range as LillyDirect's $299 to $449 brand price and below the $499 not-covered savings-program price
• No prior authorization, no lifestyle modification documentation required
• Virtual consultation, prescription, and shipment within 7 to 10 days

1. You have Medicare and do not meet the July 2026 GLP-1 Bridge criteria

• Outside the Bridge (BMI 35, or 30 or 27 with listed conditions, no type 2 diabetes), Part D still excludes Zepbound for weight loss
• Compounded tirzepatide is cash-pay, so Medicare exclusion is irrelevant
• Legal and appropriate for Medicare patients to pay cash for compounded medications

1. You want to start immediately without waiting for PA approval

• PA process takes 5 to 90 days depending on appeals
• Compounded tirzepatide consultation-to-shipment is 7 to 10 days

1. Your insurance covers Zepbound but copay is higher than compounded cost

• Some high-deductible plans have $400 to $600 per month copays for specialty tier medications
• Compounded tirzepatide at the $299 index median, or LillyDirect at $299 to $449, is cheaper

1. You qualify medically but your PCP is unfamiliar with Zepbound prescribing

• Telehealth platforms specialize in GLP-1 prescribing and have streamlined protocols
• Avoids the "I need to research this first" delay

Scenarios where brand-name Zepbound is the better option:

1. Your insurance covers it with low copay ($25 to $100 per month)

• If PA is approved and copay is low, brand is cheaper than compounded

1. You prefer FDA-approved medications over compounded

• Legitimate preference; FDA approval means standardized manufacturing and post-market surveillance
• Compounded medications are legal when a licensed pharmacy prepares them for an individual prescription, but FDA does not review them for safety, effectiveness or quality, and FDA counted more than 730 adverse-event reports for compounded tirzepatide as of May 31, 2026

1. You are in a clinical trial or research study requiring brand-name medication

• Some studies exclude compounded versions

1. Your employer or insurance plan will cover Zepbound starting next year

• If you can wait, brand coverage may be worth it

The SURMOUNT trials studied Lilly's manufactured product, not compounded preparations, so the efficacy data cannot be assumed to transfer. Compounded tirzepatide contains the same active ingredient, but its potency, purity and stability depend on the compounding pharmacy and are not FDA-verified.

The decision tree: brand vs compounded vs alternative GLP-1s

Start here: Do you meet the basic eligibility criteria?

• BMI ≥30, OR
• BMI ≥27 with documented type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease
• Age ≥18
• No contraindications (MTC, MEN2, pregnancy)

If NO: You do not qualify for Zepbound or compounded tirzepatide. Consider:

• Addressing undiagnosed comorbidities (get BP checked, lipid panel, sleep study if indicated)
• Waiting until BMI reaches 27 or 30
• Discussing alternative weight-loss options with your provider

If YES: Proceed to insurance pathway decision.

Do you have commercial insurance (not Medicare)?

• YES: Contact your insurance to verify Zepbound coverage. If covered, submit PA with required documentation. If approved, use brand. If denied and you don't want to appeal, proceed to compounded option.
• NO (Medicare, Medicaid, or uninsured): Proceed to cash-pay decision.

Cash-pay decision:

• Brand-name Zepbound: $299, $399 or $449 a month through LillyDirect with a refill within 45 days (otherwise $499 or $699); $499 through the savings program if your commercial plan excludes it; $1,291.34 average retail for single-dose pens with no offer (GoodRx, May 18, 2026)
• Compounded tirzepatide: $299 month-one median across 14 providers, range $149 to $470 (FormBlends price index, September 3, 2026)
• Compounded semaglutide: $197 month-one median, $224 month-four median (same index); a different GLP-1 with lower trial weight loss but a lower price

If cost is the deciding factor: Compounded semaglutide ($197 median) is cheapest; compounded tirzepatide ($299 median) and LillyDirect Zepbound at 2.5 mg ($299) tie, with LillyDirect rising to $399 and $449 at higher doses; the $499 not-covered savings price and full retail come last.

If efficacy is the deciding factor: Tirzepatide (brand or compounded) > semaglutide (brand or compounded) based on head-to-head data. SURMOUNT-1 showed 20.9% mean weight loss at 72 weeks on tirzepatide 15 mg. STEP 1 showed 14.9% mean weight loss at 68 weeks on semaglutide 2.4 mg (Wilding et al., New England Journal of Medicine, 2021).

If speed of access is the deciding factor: Compounded tirzepatide (7 to 10 days) > brand Zepbound without PA (if paying cash, 3 to 5 days) > brand Zepbound with PA (5 to 90 days depending on approval/appeals).

Age, pregnancy, and special population considerations

Age considerations:

• Minimum age: Adults only under the FDA label; Zepbound is not approved for patients under 18. UnitedHealthcare's September 1, 2026 policy sets its own floor at over 16 years for Zepbound, while Wegovy injection is approved and covered down to age 12, making it the usual GLP-1 for adolescents.

• Maximum age: No upper age limit in the FDA label. Clinical judgment applies for patients over 75. The SURMOUNT-1 trial included patients up to age 75, but very few over 70. Older adults have higher risk of GI side effects, dehydration, and sarcopenia (muscle loss) during rapid weight loss. Providers typically use lower starting doses and slower titration in patients over 70.

• Geriatric considerations: Patients over 65 should have renal function (eGFR) and nutritional status assessed before starting. Protein intake of 1.0 to 1.2 g/kg/day is recommended to preserve lean mass during weight loss. Resistance training is especially important in this age group.

Pregnancy and breastfeeding:

• Pregnancy: Absolute contraindication. Tirzepatide has not been studied in pregnant humans. Animal studies show fetal risk. Discontinue at least 2 months before attempting conception (5 half-lives for clearance). The half-life of tirzepatide is approximately 5 days, so 25 days is the minimum washout period.

• Breastfeeding: Not recommended. It is unknown whether tirzepatide is excreted in human breast milk. The molecular weight (4,813 Da) suggests minimal transfer, but no data exists. Most providers recommend waiting until breastfeeding is complete.

• Postpartum weight loss: Many patients ask about starting Zepbound postpartum. If not breastfeeding, treatment can start 6 to 8 weeks postpartum once weight has stabilized. If breastfeeding, wait until weaning is complete.

Reproductive age considerations:

• Tirzepatide may affect the absorption of oral contraceptives due to delayed gastric emptying. Use backup contraception (condoms, IUD) during the first 4 weeks of treatment and for 4 weeks after each dose escalation.

• Patients with PCOS often see improved ovulation and fertility with weight loss. Unintended pregnancy risk increases. Reliable contraception is essential.

Renal impairment:

• No dose adjustment needed for mild to moderate renal impairment (eGFR 30 to 89 mL/min).
• Severe renal impairment (eGFR <30) or end-stage renal disease: not studied extensively, but tirzepatide is not renally cleared. Can be used under close provider supervision. GI side effects may be worse.

Hepatic impairment:

• No dose adjustment needed for mild to moderate hepatic impairment.
• Severe hepatic impairment: not studied. Use with caution.

Bariatric surgery history:

• Prior bariatric surgery (gastric bypass, sleeve gastrectomy) is NOT a contraindication to Zepbound.
• Some patients regain weight years after surgery and benefit from GLP-1 therapy.
• Absorption may be altered post-bypass; subcutaneous injection bypasses GI absorption issues.
• Risk of hypoglycemia is higher in post-bypass patients on tirzepatide; monitor closely.

What to bring to your provider appointment

If you are pursuing Zepbound through your primary care provider or endocrinologist, come prepared. The appointment will go faster and approval odds improve if you bring:

Required documentation:

1. Current weight and height

• Measured at home on a calibrated scale (bathroom scales are fine if recently zeroed)
• Height in inches or centimeters
• Providers will re-measure, but having your numbers ready helps

1. Medical history summary

• List of current medications (names and doses)
• List of diagnosed medical conditions
• Prior weight-loss attempts and outcomes (dates, methods, results)
• Family history of thyroid cancer, MEN2, or other endocrine disorders

1. Recent lab results (if available)

• Lipid panel (total cholesterol, LDL, HDL, triglycerides) from past 12 months
• HbA1c or fasting glucose from past 12 months
• TSH from past 12 months
• Comprehensive metabolic panel (CMP) including creatinine and eGFR

1. Blood pressure log (if claiming hypertension as comorbidity)

• Home BP readings taken twice daily for 7 to 14 days
• Include date, time, systolic/diastolic readings
• If you don't have a home BP cuff, many pharmacies offer free BP checks

1. Sleep study report (if claiming sleep apnea as comorbidity)

• Polysomnography report showing AHI ≥5
• CPAP compliance data if you use CPAP

Helpful but not required:

1. Weight loss timeline

• Graph or log of weight over the past 6 to 12 months
• Shows documented attempts at diet and exercise
• Useful for insurance PA documentation

1. Dietitian or nutritionist records

• Visit notes from registered dietitian
• Meal plans or food logs
• Demonstrates "lifestyle modification" for PA

1. Exercise log

• Gym membership records
• Fitness tracker data (Fitbit, Apple Watch)
• Personal trainer records

1. Insurance card and policy information

• Bring physical card or have member ID ready
• Know whether your plan requires PA for specialty medications

Questions to ask your provider:

• Do I meet the eligibility criteria for Zepbound?
• Which comorbidities do I have that qualify me?
• Do you foresee any contraindications based on my history?
• Will you handle the prior authorization, or do I need to contact insurance?
• What is the expected timeline for PA approval?
• If insurance denies, what are my options?
• What side effects should I expect, and how do we manage them?
• What is the titration schedule you recommend?
• How often do I need follow-up appointments?

Most providers appreciate patients who come prepared. It signals you are serious about treatment and understand the process.

Steelmanning the case against Zepbound qualification

A thoughtful clinician might argue that the current eligibility criteria are too broad and that many patients who qualify should not start Zepbound. Here is the strongest version of that argument:

The case against broad Zepbound eligibility:

1. The BMI threshold is arbitrary and fails to account for body composition. A muscular athlete with BMI 31 and 12% body fat does not have obesity. A sedentary person with BMI 26 and 35% body fat does. BMI is a population-level screening tool, not a diagnostic criterion. Qualifying patients based on BMI alone medicalizes normal weight variation and expands the treatment pool beyond those who will benefit.

1. The comorbidity list conflates correlation with causation. Hypertension and dyslipidemia correlate with obesity but are not always caused by it. A patient with familial hypercholesterolemia has high LDL regardless of weight. Treating that patient with Zepbound for "dyslipidemia" misidentifies the problem. The comorbidity should be weight-responsive, not just weight-associated.

1. The "lifestyle modification" requirement is performative. Requiring 3 to 6 months of documented diet and exercise failure creates paperwork without improving outcomes. Patients who have struggled with weight for years do not need to prove they tried and failed. The requirement delays access and selects for patients with good documentation, not patients who need treatment most.

1. Medication-first approaches bypass the underlying behavior change. Zepbound works by reducing appetite and slowing gastric emptying. It does not teach portion control, meal planning, or stress management. When patients stop the medication (due to cost, side effects, or supply issues), weight regain is common. A 2023 analysis of the SURMOUNT-1 extension study showed patients regained 14% of lost weight within 17 weeks of stopping tirzepatide (Aronne et al., Diabetes, Obesity and Metabolism, 2024). Qualifying patients without requiring concurrent behavioral intervention sets them up for yo-yo weight cycling.

1. The long-term safety data does not yet exist. Zepbound has been on the market since November 2023. The longest trial data is 72 weeks (SURMOUNT-1). We do not know the 5-year or 10-year safety profile. The thyroid C-cell tumor signal in rodents has not been observed in humans, but the post-market surveillance window is short. Qualifying tens of millions of patients for a medication with 18 months of real-world data is a population-level experiment.

The rebuttal:

These concerns are valid but do not outweigh the benefits for most patients who meet criteria:

1. BMI is imperfect but correlated with health risk at the population level. The edge cases (muscular athletes) are rare. For the vast majority of patients with BMI ≥30, excess adiposity is the issue. Body composition testing (DEXA, bioimpedance) can refine the assessment, but requiring it for every patient creates access barriers.

1. Weight loss improves comorbidities regardless of causation. Even if hypertension is not purely weight-driven, a 15% weight loss lowers systolic BP by an average of 5 to 10 mmHg (look-AHEAD trial, Wadden et al., Diabetes Care, 2014). The mechanism matters less than the outcome.

1. Lifestyle modification requirements are insurance-driven, not evidence-driven. Providers and patients agree the 6-month documentation rule is bureaucratic. The solution is policy change, not withholding treatment.

1. Behavioral intervention works best when combined with medication, not before it. The STEP 1 trial included diet and exercise counseling alongside semaglutide. The combination produced better outcomes than either alone. Requiring behavior change first is the wrong sequence.

1. The safety signal is reassuring so far. Post-market surveillance through April 2026 has not identified new safety concerns beyond those seen in trials. The thyroid cancer signal has not materialized in humans. Pancreatitis and gallbladder events occur at expected rates. Longer-term data will refine risk estimates, but current data supports use in eligible patients.

The strongest argument for broad qualification is this: obesity is a chronic disease with serious health consequences, and we finally have a medication that works. Restricting access based on hypothetical future risks or preference for behavioral intervention first denies effective treatment to patients who need it now.

What insurers actually check in 2026: UnitedHealthcare's Zepbound criteria as the template

Most articles paraphrase insurer rules. Here is one written down. UnitedHealthcare publishes its pharmacy prior authorization policy for weight-loss drugs, and the version effective September 1, 2026 is the most current large-payer document we could find.

UnitedHealthcare commercial weight-loss policy, effective September 1, 2026	Zepbound criterion
Indication	Appetite suppression or weight loss, or moderate to severe obstructive sleep apnea
Age	Over 16 years (Wegovy injection, Saxenda, Qsymia and Xenical: 12 and older)
Lifestyle	Used as an adjunct to lifestyle modification (dietary or caloric restriction, exercise, behavioral support, community-based program)
BMI	30 kg/m2 or higher, or a pediatric BMI above the 95th percentile; or 27 kg/m2 or higher with a weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes or sleep apnea
Initial authorization	6 months for Zepbound (5 months for Wegovy, 4 months for Contrave)
Renewal	Weight loss of at least 5 percent of baseline body weight plus continued lifestyle modification, then 12 months
Plans that exclude weight-loss drugs	Separate nonformulary Zepbound criteria apply; North Dakota small-group and individual EHB plans require BMI 40 or higher or MASH

Two things stand out against the folklore. The policy does not require a documented 3-to-6-month lifestyle failure, only that the drug be used alongside lifestyle modification. And it does not list a step through phentermine or metformin for Zepbound. Other payers write their own rules, and self-funded employers can exclude weight-loss drugs entirely, in which case UnitedHealthcare's nonformulary criteria apply instead.

Who is covered at work: KFF's 2025 numbers by employer size

Firms offering health benefits (KFF EHBS, October 22, 2025)	Cover GLP-1s for weight loss
200 to 999 workers	16 percent
1,000 to 4,999 workers	30 percent
5,000 or more workers	43 percent

Among firms that do cover them, about one-third require a dietitian, case manager or lifestyle program as a condition, and only 1 percent of non-covering firms told KFF they were very likely to add coverage within 12 months. Healthline (January 15, 2026) cites a separate estimate that 33 percent of plans and employers covered obesity GLP-1s in 2024. Your Summary of Benefits, not the carrier's national formulary, decides whether Zepbound is on your plan.

Medicare: the July 2026 Bridge door for the Zepbound KwikPen

Until June 30, 2026 the honest answer for Medicare was no, except for OSA. On July 1, 2026 CMS opened the Medicare GLP-1 Bridge (CMS provider page, last updated August 6, 2026; Lilly's Zepbound Medicare page).

Bridge rule (CMS, last updated August 6, 2026)	Detail
Dates	July 1, 2026 through December 31, 2027
Copay	$50 per 30-day supply; the copay does not count toward the Part D deductible or the $2,100 out-of-pocket cap
Drugs	Wegovy pen and pill, Zepbound KwikPen only (not single-dose pens or vials), Foundayo
Who qualifies	BMI 35 or higher; or BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or worse; or BMI 27 or higher with prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease
Who is excluded	People with type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH use regular Part D coverage instead
Prior authorization	Pharmacy transmits the request within 24 to 72 hours; decision within 72 hours; no appeals, but a corrected request can be resubmitted; approval is valid through December 31, 2027 for refills and dose changes

For Zepbound specifically, only the KwikPen is covered; single-dose pens and vials are not. Lilly's Medicare page says prior authorization is handled at the first fill. Because the Bridge excludes type 2 diabetes and OSA, a Medicare patient with obesity and sleep apnea uses the OSA indication through regular Part D instead, and a Medicare patient with diabetes is routed to Mounjaro under Part D.

Qualifying but uncovered: 2026 cash prices side by side

Option (checked September 4 to 5, 2026)	Monthly price	Fine print
LillyDirect Zepbound vial or KwikPen	$299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg)	The $449 tier requires a refill within 45 days of the previous fill; otherwise $499 or $699 (Lilly). Walmart pickup at the same price.
Lilly savings program, plan does not cover	$499	Commercial insurance required; program expires December 31, 2026
Lilly savings card, plan covers	As little as $25	Savings caps $100, $200, $300 per 1-, 2-, 3-month fill; $1,300 a year; 13 fills
Retail with no offer	$1,291.34 average for single-dose pens; $599.85 for KwikPens and vials	GoodRx, updated May 18, 2026; list price $499 to $1,086
Compounded tirzepatide, 14-provider median	$299 month one (range $149 to $470); $299 month four	FormBlends price index, September 3, 2026; not FDA-approved
FormBlends compounded tirzepatide (our own row)	Current price on the product page and in our price index	Same index rules as every other provider

The practical read: for a patient who qualifies medically but has no coverage, brand Zepbound at the 2.5 mg starting dose now costs the same as the compounded median, and stays within $150 of it at higher doses. Compounded pricing is flat across doses in the Compounded GLP-1 Price Index; brand steps up.

Zepbound in Canada (for readers searching from there)

Health Canada authorized Zepbound for chronic weight management on May 13, 2025, and on June 16, 2026 issued a Notice of Compliance for moderate to severe obstructive sleep apnea in adults with obesity (BMI 30 or higher), per Lilly Canada's release. The qualifying criteria mirror the U.S. label: adults with obesity, or overweight with a weight-related condition. Two differences matter for Canadian readers of this U.S. article. The LillyDirect $299 to $449 prices, the U.S. savings card and the Medicare Bridge do not apply in Canada; provincial and private drug plan rules do. And U.S. telehealth compounding platforms, including FormBlends, do not ship to Canada.

OSA as a qualifying diagnosis (FDA, December 20, 2024)

On December 20, 2024 FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, the first drug approved for OSA, based on two 52-week trials in 469 adults. This created a second route to qualify. Under UnitedHealthcare's September 1, 2026 policy, a documented OSA diagnosis with obesity satisfies the indication criterion on its own; the BMI 27 comorbidity pathway is not needed. For Medicare, OSA is a coverable Part D indication but is excluded from the $50 GLP-1 Bridge, so an OSA patient goes through regular Part D prior authorization. Insurers generally want a sleep study; the label describes the population as adults with obesity and moderate to severe OSA.

FAQ

What BMI do you need to qualify for Zepbound?

You need a BMI of 30 or higher, or a BMI of 27 or higher if you have at least one weight-related health condition like type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease. BMI is calculated as weight in kilograms divided by height in meters squared.

Can I get Zepbound if my BMI is 26?

No, not under the FDA-approved indication. The minimum BMI is 27, and even then you need a documented comorbidity. Some providers prescribe off-label for BMI below 27, but insurance will not cover it and most telehealth platforms follow the labeled indication.

Do I need a prescription for Zepbound?

Yes. Zepbound is a prescription-only medication. You need a consultation with a licensed healthcare provider (physician, nurse practitioner, or physician assistant) who will assess your eligibility and write a prescription if appropriate.

Does insurance cover Zepbound?

It depends on the plan sponsor: KFF's 2025 employer survey found 16 percent of firms with 200 to 999 workers, 30 percent with 1,000 to 4,999 and 43 percent with 5,000 or more covered GLP-1s for weight loss, nearly always with prior authorization. Since July 1, 2026 Medicare covers the Zepbound KwikPen at $50 a month through the GLP-1 Bridge for enrollees meeting BMI criteria. If insurance says no, LillyDirect charges $299 to $449 and compounded tirzepatide ran a $299 median on September 3, 2026.

What medical conditions qualify you for Zepbound?

The five recognized weight-related comorbidities are type 2 diabetes, hypertension (high blood pressure), dyslipidemia (high cholesterol or triglycerides), obstructive sleep apnea, and cardiovascular disease. You need at least one of these documented conditions if your BMI is between 27 and 29.9.

Can I get Zepbound if I have prediabetes?

Prediabetes (HbA1c 5.7 to 6.4%) does not officially qualify under most insurance policies, which require a diagnosis of type 2 diabetes. Some providers prescribe off-label for prediabetes, especially if BMI is ≥30. Cash-pay and compounded options are more flexible on this criterion.

What disqualifies you from taking Zepbound?

Absolute disqualifiers include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN2), current pregnancy or planning pregnancy within 2 months, and known severe allergy to tirzepatide. Relative contraindications include recent pancreatitis, severe gastroparesis, and active eating disorders.

Can I take Zepbound if I had my gallbladder removed?

Yes. Prior cholecystectomy (gallbladder removal) is not a contraindication. In fact, it eliminates one of the risks of rapid weight loss (gallstone formation). Active gallbladder disease may require treatment before starting Zepbound.

How long does it take to get approved for Zepbound?

If paying cash without insurance, 3 to 5 days from prescription to pharmacy pickup. If using insurance, prior authorization takes 5 to 10 business days if approved on first submission, or 30 to 90 days if denied and appealed. Compounded tirzepatide through telehealth platforms takes 7 to 10 days from consultation to delivery.

Do I need to try other weight-loss medications before Zepbound?

Not according to FDA criteria. Some insurance plans require a documented trial of an older medication first, but UnitedHealthcare's commercial weight-loss policy effective September 1, 2026 lists no such step for Zepbound, only use alongside lifestyle modification. This is a coverage policy, not a medical requirement, and it varies by plan. Cash-pay and compounded options do not have this requirement.

Can I get Zepbound if I am over 65?

Yes. There is no upper age limit in the FDA approval. Providers use clinical judgment for patients over 75, often starting at lower doses and titrating more slowly. Renal function and nutritional status should be assessed before starting.

What is the difference between Zepbound and compounded tirzepatide?

Both contain tirzepatide. Zepbound is the FDA-approved product manufactured by Eli Lilly; compounded tirzepatide is prepared by a state-licensed compounding pharmacy and is not FDA-approved or reviewed for safety, effectiveness or quality. On price they now overlap: compounded tirzepatide had a $299 month-one median across 14 providers on September 3, 2026, and LillyDirect sells brand Zepbound for $299, $399 or $449 by dose with a refill within 45 days.

Who is usually eligible to be prescribed Zepbound?

Adults with a BMI of 30 or higher; adults with a BMI of 27 or higher plus a weight-related condition such as type 2 diabetes, hypertension, dyslipidemia or sleep apnea; and adults with obesity who have moderate to severe obstructive sleep apnea (Zepbound label, revised 08/2026; FDA OSA approval December 20, 2024). People with a personal or family history of medullary thyroid carcinoma or MEN 2 are excluded. Insurers such as UnitedHealthcare add age over 16 and lifestyle-modification requirements.

What comorbidities qualify for Zepbound at a BMI of 27 to 29.9?

The label says at least one weight-related comorbid condition without a closed list; SURMOUNT-1 enrolled BMI 27 to 30 patients with dyslipidemia, hypertension, sleep apnea or cardiovascular disease. UnitedHealthcare's policy effective September 1, 2026 gives dyslipidemia, hypertension, type 2 diabetes and sleep apnea as examples. Medicare's GLP-1 Bridge is stricter at BMI 27: it accepts only prediabetes, prior heart attack, prior stroke or symptomatic peripheral artery disease (CMS, August 6, 2026).

Is Zepbound approved for sleep apnea?

Yes. FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity on December 20, 2024, based on two 52-week trials in 469 adults, and the indication appears in the label revised 08/2026. Health Canada followed on June 16, 2026. For Medicare, OSA is a coverable Part D indication but is excluded from the $50 GLP-1 Bridge, which is limited to weight-management criteria in people without diabetes or OSA.

What are the Zepbound prior authorization criteria in 2026?

They vary by payer, but UnitedHealthcare's published commercial policy effective September 1, 2026 is representative: age over 16, BMI 30 or higher (or 27 with a comorbidity) or an OSA diagnosis, and use as an adjunct to lifestyle modification. Approval lasts 6 months; renewal requires at least 5 percent weight loss from baseline and continued lifestyle changes, then runs 12 months. Medicare's Bridge decides within 72 hours and allows no appeal, only resubmission.

Related guides

• How Do You Qualify for Ozempic? The Complete Medical Eligibility Criteria and What Most Providers Actually Check
• How to Qualify for Mounjaro (Tirzepatide): The Medical Eligibility Criteria, Insurance Requirements, and Alternative Pathways
• Should I Take Wegovy? The Evidence-Based Decision Framework
• How to Qualify for Semaglutide: The Complete Medical Eligibility Guide for 2026
• Do I Qualify for Ozempic? The Complete FDA-Approved Criteria, Off-Label Use, and What Your Provider Actually Evaluates
• How to Qualify for Ozempic: The Complete Medical Criteria, Insurance Requirements, and Alternative Pathways

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes, Obesity and Metabolism. 2024.
4. Wadden TA et al. Weight Loss with Intensive Lifestyle Intervention in Type 2 Diabetes: Look AHEAD Trial Results. Diabetes Care. 2014.
5. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
6. Eli Lilly. Zepbound (tirzepatide) prescribing information, revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
7. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
8. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
9. Wharton S et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. 2023.
10. KFF. 2025 Employer Health Benefits Survey, October 22, 2025. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
11. Removed September 2026: an AHIP survey citation printed here earlier could not be located; the appeal-rate statistics attributed to it have been deleted from this article.
12. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
13. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
15. Eli Lilly. Zepbound (tirzepatide) prescribing information, revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
16. U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea (Zepbound), December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
17. UnitedHealthcare. Pharmacy prior authorization notification: weight loss (Wegovy, Zepbound, Contrave and others), effective September 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
18. KFF. 2025 Employer Health Benefits Survey (GLP-1 weight-loss coverage by firm size; 67 percent of covered workers in self-funded plans), October 22, 2025. https://www.kff.org/health-costs/2025-employer-health-benefits-survey/
19. Healthline. Is Zepbound covered by insurance? (33 percent of plans and employers covered obesity GLP-1s in 2024), January 15, 2026. https://www.healthline.com/health/drugs/is-zepbound-covered-by-insurance
20. Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge: information for providers (July 1, 2026 to December 31, 2027; Wegovy, Zepbound KwikPen, Foundayo; BMI criteria; 72-hour decisions), last updated August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
21. Medicare.gov. Weight-loss drug coverage and the Medicare GLP-1 Bridge ($50 monthly copay, does not count toward deductible or out-of-pocket limits), seen September 5, 2026. https://www.medicare.gov/coverage/weight-loss-drugs
22. Eli Lilly. Zepbound and the Medicare GLP-1 Bridge ($50 a month for the KwikPen; prior authorization at first fill), seen September 5, 2026. https://zepbound.lilly.com/medicare
23. Eli Lilly. Zepbound coverage and savings (savings card $25 with $100, $200 and $300 caps, $1,300 a year, 13 fills, through December 31, 2026; $499 when a commercial plan does not cover it), seen September 4, 2026. https://zepbound.lilly.com/coverage-savings
24. Eli Lilly. LillyDirect Zepbound self-pay pricing ($299, $399, $449 with a refill within 45 days; otherwise $499 or $699), seen September 4, 2026. https://www.lilly.com/lillydirect/zepbound
25. GoodRx. How much does Zepbound cost without insurance? (list $499 to $1,086; average retail $1,291.34 for single-dose pens and $599.85 for KwikPens and vials; $299 KwikPen offer), updated May 18, 2026. https://www.goodrx.com/zepbound/weight-loss-tirzepatide-cost
26. Eli Lilly Canada. Health Canada authorizes Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, June 16, 2026. https://www.lilly.com/en-ca/news/press-releases/zepbound-osa-noc
27. Novo Nordisk, NovoCare. Check your Wegovy coverage (prior authorization can take up to 10 business days; no insurance coverage yet for Wegovy 7.2 mg; Medicare GLP-1 Bridge $50), seen September 5, 2026. https://www.novocare.com/patient/medicines/wegovy/check-coverage.html
28. Penn LDI. Patients face new barriers for GLP-1 drugs like Wegovy and Ozempic (summary of Klebanoff et al., JAMA, September 25, 2025), January 21, 2026. https://ldi.upenn.edu/our-work/research-updates/patients-face-new-barriers-for-glp-1-drugs-like-wegovy-and-ozempic/
29. FormBlends. Compounded GLP-1 Price Index methodology and current medians, data as of September 3, 2026. https://formblends.com/report/data/compounded-glp1-price-index
30. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (adverse-event report counts as of May 31, 2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ {"@type": "Question", "name": "What BMI do you need to qualify for Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "You need a BMI of 30 or higher, or a BMI of 27 or higher if you have at least one weight-related health condition like type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease. BMI is calculated as weight in kilograms divided by height in meters squared."}}, {"@type": "Question", "name": "Can I get Zepbound if my BMI is 26?", "acceptedAnswer": {"@type": "Answer", "text": "No, not under the FDA-approved indication. The minimum BMI is 27, and even then you need a documented comorbidity. Some providers prescribe off-label for BMI below 27, but insurance will not cover it and most telehealth platforms follow the labeled indication."}}, {"@type": "Question", "name": "Do I need a prescription for Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "Yes. Zepbound is a prescription-only medication. You need a consultation with a licensed healthcare provider (physician, nurse practitioner, or physician assistant) who will assess your eligibility and write a prescription if appropriate."}}, {"@type": "Question", "name": "Does insurance cover Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "It depends on the plan sponsor: KFF's 2025 employer survey found 16 percent of firms with 200 to 999 workers, 30 percent with 1,000 to 4,999 and 43 percent with 5,000 or more covered GLP-1s for weight loss, nearly always with prior authorization. Since July 1, 2026 Medicare covers the Zepbound KwikPen at $50 a month through the GLP-1 Bridge for enrollees meeting BMI criteria. If insurance says no, LillyDirect charges $299 to $449 and compounded tirzepatide ran a $299 median on September 3, 2026."}}, {"@type": "Question", "name": "What medical conditions qualify you for Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "The five recognized weight-related comorbidities are type 2 diabetes, hypertension (high blood pressure), dyslipidemia (high cholesterol or triglycerides), obstructive sleep apnea, and cardiovascular disease. You need at least one of these documented conditions if your BMI is between 27 and 29.9."}}, {"@type": "Question", "name": "Can I get Zepbound if I have prediabetes?", "acceptedAnswer": {"@type": "Answer", "text": "Prediabetes (HbA1c 5.7 to 6.4%) does not officially qualify under most insurance policies, which require a diagnosis of type 2 diabetes. Some providers prescribe off-label for prediabetes, especially if BMI is ≥30. Cash-pay and compounded options are more flexible on this criterion."}}, {"@type": "Question", "name": "What disqualifies you from taking Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "Absolute disqualifiers include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN2), current pregnancy or planning pregnancy within 2 months, and known severe allergy to tirzepatide. Relative contraindications include recent pancreatitis, severe gastroparesis, and active eating disorders."}}, {"@type": "Question", "name": "Can I take Zepbound if I had my gallbladder removed?", "acceptedAnswer": {"@type": "Answer", "text": "Yes. Prior cholecystectomy (gallbladder removal) is not a contraindication. In fact, it eliminates one of the risks of rapid weight loss (gallstone formation). Active gallbladder disease may require treatment before starting Zepbound."}}, {"@type": "Question", "name": "How long does it take to get approved for Zepbound?", "acceptedAnswer": {"@type": "Answer", "text": "If paying cash without insurance, 3 to 5 days from prescription to pharmacy pickup. If using insurance, prior authorization takes